Veracyte Inc. Stock
Your prediction
Veracyte Inc. Stock
A loss of -2.160% shows a downward development for Veracyte Inc..
So far the community has only identified positive things for Veracyte Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Veracyte Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Veracyte Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Veracyte Inc. | -2.160% | -6.050% | -7.112% | 129.183% | 32.417% | 92.218% | 30.246% |
| Evolus Inc | -0.040% | -0.496% | -14.130% | -33.154% | -4.330% | -42.703% | -41.085% |
| Heron Therapeutics Inc. | -1.990% | 2.964% | 15.558% | -71.508% | -61.329% | -69.229% | -95.846% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
News
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.
Jonathan Wygant, Vice President and Chief Accounting Officer of Veracyte (NASDAQ:VCYT), reported the exercise of 24,000 options and immediate open-market sale of the same number of shares for a
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally
Karin Eastham, a director of Veracyte (NASDAQ:VCYT), reported the sale of 3,729 shares of common stock in multiple open-market transactions on June 18, 2026, as detailed in the SEC Form 4 filing.
Why Veracyte Stock Is Skyrocketing Higher This Week
Shares of leading diagnostics platform and cancer-detecting genomic test provider Veracyte (NASDAQ: VCYT) are up 23% over the last week as of market close Thursday, after the company reported